Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma

Open access
Lee, Anne W., Ng, Wai Tong, Pan, Jian Ji, Chiang, Chi-Leung, Poh, Sharon S., Choi, Horace C., Ahn, Yong Chan, AlHussain, Hussain, Corry, June, Grau, Cai, Grégoire, Vincent, Harrington, Kevin J., Hu, Chao Su, Kwong, Dora L., Langendijk, Johannes A., Le, Quynh Thu, Lee, Nancy Y., Lin, Jin Ching, Lu, Tai Xiang, Mendenhall, William M., O'Sullivan, Brian, Ozyar, Enis, Peters, Lester J., Rosenthal, David I., Sanguineti, Giuseppe, Soong, Yoke Lim, Tao, Yungan, Yom, Sue S., Wee, Joseph T. · 2019 · International Journal of Radiation Oncology*Biology*Physics

Abstract

PURPOSE The treatment of nasopharyngeal carcinoma (NPC) requires high radiation doses. The balance of the risks of local recurrence due to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformality is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the ALARP (As Low As Reasonably Practicable) principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference. METHODS A literature search on dose tolerances and normal tissue complications following treatment for NPC was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications and/or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then re-circulated to the whole panel for review and re-consideration. Based on the comments of the panel, a refined second proposal was re-circulated to the same panel. The current guideline was based on majority voting following repeated iteration for final agreement. RESULTS Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed. CONCLUSIONS Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and patient's acceptance of optimal balance of risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2019.06.2540

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 183

Metadata

Authors
Lee, A. W., Ng, W. T., Pan, J. J., Chiang, C.-L., Poh, S. S., Choi, H. C., Ahn, Y. C., AlHussain, H., Corry, J., Grau, C., Grégoire, V., Harrington, K. J., Hu, C. S., Kwong, D. L., Langendijk, J. A., Le, Q. T., Lee, N. Y., Lin, J. C., Lu, T. X., Mendenhall, W. M., O'Sullivan, B., Ozyar, E., Peters, L. J., Rosenthal, D. I., Sanguineti, G., Soong, Y. L., Tao, Y., Yom, S. S., & Wee, J. T.
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2019-11
Volume
105
Issue
3
Pages
567-580
ISSN
0360-3016 (ISSN-L)
OpenAlex
W2954237769
Cited by
183
References
1
FWCI
16.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.